@itb-med.com
ITBMed is developing Siplizumab, a monoclonal humanized IgG1ΒK antibody directed towards the human CD2 molecule.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
About
Description
ITBMed is a biopharmaceutical company that specializes in developing specific immunomodulatory biologics for various medical conditions, including transplantation, autoimmunity, neurodegenerative diseases, and gene therapy. Their flagship product, siplizumab, is a monoclonal antibody in clinical development that has shown immense potential in transforming the lives of organ transplant patients. Siplizumab has been used in over 700 patients in Phase I/II trials and has been designated as an Orphan Drug in both the US and Europe.
It offers revolutionary improvements in the treatment of transplant patients by allowing the complete discontinuation of immunosuppression treatment, minimizing toxicities associated with standard-of-care immunosuppression, and improving quality of life. ITBMed also collaborates with esteemed US and European universities for preclinical research and development, which may lead to new breakthroughs and treatments. With a world-leading team of medical and scientific advisors and a board of directors with extensive expertise in the pharmaceutical industry, ITBMed is at the forefront of advancing medical innovations.
They are based in New York, USA, and Stockholm, Sweden
Company Type
Privately Held
Company Size
11-50
Year Founded
2016
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories